Abstract

Hepatic steatosis involves an imbalance between the processes of the hepatocytes’ lipid uptake and lipid elimination, an overproduction results in the accumulation of excess triglycerides in the cells of the liver. Normally about 5% of the cells contain triglyceride; in steatosis this may exceed 50%. Under 50% the condition is called fatty infiltration, and over 50% it is called fatty liver. In mild forms this does not necessarily lead to disorders in cell functions, but in more severe forms it does; it often precedes the death of the cell. Fatty liver can be considered a pathologic condition which makes the liver more susceptible to other toxic influences. It is not a genuine disease; in most cases it is associated with a noxious state or other pathologic process. Alcohol-induced fatty liver is a current epidemie. The abnormal accumulation of fat in parenchymal organs, including the liver, is called fatty transformation or steatosis. Alone and limited to a certain degree of severity (the appearance of fibrosis), it represents a reversible damage; upon cessation of the underlying cause the liver clears its excess triglyceride content. The treatment is to be aimed at the underlying process; up to now there is no known specific medicine that could clearly reduce the fat accumulated in the hepatocytes. Although the etiologic factors of these diseases differ from each other, the pathological changes in the liver are very similar, thus certain drugs could be equally effective for treating them both. Metadoxine is one of those drugs, mainly due to its liver-protective effect against damage from free radicals. As an effective antioxidant, metadoxine regulates glutathione levels in the liver and throughout the body, thus positively influencing the maintenance of systemic redox homeostasis. The authors discuss in detail the effect of metadoxine in the treatment of fatty liver diseases (alcoholic and non-alcoholic), they also review the effect of metadoxine in both in vitro and in vivo experimental conditions.

  • [1]. L. A. Adams K. D. Lindor 2007 Nonalcoholic fatty liver disease Ann. Epidemiol. 17 863869.

  • [2]. D. H. Akbar A. H. Kawther 2006 Non-alcoholic fatty liver disease and metabolic syndrome: what we know and what we dont't know Med. Sci. Monit. 12 2326.

    • Search Google Scholar
    • Export Citation
  • [3]. G. Targher L. Bertolini R. Padovani et al.2007 Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients Diab. Care 30 12121218.

    • Search Google Scholar
    • Export Citation
  • [4]. K. Bogdanova H. Poczatkova L. Uherkova et al.2006 Non-alcoholic fatty liver disease (NAFLD) — a novel common aspect of the metabolic syndrome Biomed. Pap. Med. Fac. Univ. Papacky Olomouc Czech. Repub. 150 101104.

    • Search Google Scholar
    • Export Citation
  • [5]. J. Fehér E. Németh G. Lengyel 2005 Non-alcoholic steatohepatitis (NASH) — is it a part of the metabolic syndrome? Arch. Med. Sci. 1 3747.

    • Search Google Scholar
    • Export Citation
  • [6]. R. Felicioli I. Saracchi A. M. Flagiello et al.1980 Effects of pyridoxine-pyrrolidon-carboxylate on hepatic and cerebral ATP levels in ethanol treated rats Int. J. Clin. Pharmacol. Ther. Toxicol. 18 277280.

    • Search Google Scholar
    • Export Citation
  • [7]. M. Baldacci R. Catalani C. Banoli et al.1982 Effects of pyridoxine-pyrrolidone-carboxylate on hepatic adenosine triphosphate levels in rals Bol. Soc. Ital. Biol. Sper. 58 16431649.

    • Search Google Scholar
    • Export Citation
  • [8]. S. Marchi A. Polloni F. Costa et al.1990 Liver triglyceride accumulation and chronic ethanol administration: a possible proteclive role of metadoxina and ubiquinone Int. J. Tissue React. 12 247250.

    • Search Google Scholar
    • Export Citation
  • [9]. R. Felicioli I. Saracchi A. M. Flagiello et al.1980 Effects or pyridoxine-pyrrolidon-carboxylate on hcpatic and cerebral ATP levels in ethanol treated rats Int. J. Clin. Pharm. Ther. 18 277280.

    • Search Google Scholar
    • Export Citation
  • [10]. S. Santoni P. Corradini M. Zocchil et al.1989 Metadoxinc in alcohol related pathology Clin. Ther. 130 115122.

  • [11]. A. Pár 2000 Treatment of alcoholic liver diseases. Abstinence, nutritional support, drug therapy, liver transplantation Orv. Hetil. 141 827833.

    • Search Google Scholar
    • Export Citation
  • [12]. K. Hagymási A. Blázovics G. Lengyel et al.2001 Oxidative damage in alcoholic liver disease Eur. J. Gastroenterol. Hepatol. 3 4953.

  • [13]. K. Hagymási A. Blázovics G. Lengyel et al.2004 Investigation of redox homeostasis of liver in experimental and human studies Acta Pharm. Hung. 74 5163.

    • Search Google Scholar
    • Export Citation
  • [14]. K. Hagymási A. Blázovics 2004 Antioxidants in liver protection Orv. Hetil. 145 14211425.

  • [15]. J. Caballeria A. Pares C. Bru et al.1998 Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver J. Hepatol. 28 5460.

    • Search Google Scholar
    • Export Citation
  • [16]. L. Váli A. Blázovics J. Fehér 2005 The therapeutic effect of metadoxine on alcoholic and non-alcoholic steatohepatitis Orv. Hetil. 146 24092414.

    • Search Google Scholar
    • Export Citation
  • [17]. M. C. Diaz Martinez A. Diaz Martinez V. Villamil Salcedo et al.2002 Efficacy of metadoxine in the management of acute alcohol intoxication J. Int. Med. Res. 30 4451.

    • Search Google Scholar
    • Export Citation
  • [18]. N. N. Vedrov N. Gnezdilov 2001 Metadoxyl in combined treatment or alcohol damage to the liver Klinicheskaia Meditsina 79 5658.

  • [19]. S. Marchi A. Polloni F. Costa et al.1990 Liver triglyceride accumulation after chronic ethanol administration: a possible protective role of metadoxina and ubiquinone Int. J. Tissue React. 12 247250.

    • Search Google Scholar
    • Export Citation
  • [20]. G. Bono E. Sinforiani P. Merlo et al.1991 Alcoholic abstinence syndrome: short-term treatment with metadoxine Int. J. Clin. Pharm. Res. 11 3540.

    • Search Google Scholar
    • Export Citation
  • [21]. X. Pares A. I. Moreno J. M. Peralba et al.1991 Action of metadoxine on isolated human and rat alcohol and aldehyde dehydrogenases. Effect on enzymes in chronic ethanol-fed rats Method Find. Exp. Clin. 13 3742.

    • Search Google Scholar
    • Export Citation
  • [22]. S. Santoni P. Corradini M. Zocchi et al.1989 Metadoxine in alcohol-related pathology Clin Ter. 130 115122.

  • [23]. G. Corsini E. Gelso G. Giuliano 1992 Effects of metadoxine on main biohumoral changes induced by chronic alcoholism Clin. Ther. 140 251257.

    • Search Google Scholar
    • Export Citation
  • [24]. V. Calabrese G. Bombaci A. Calderone et al.1993 Effects of metadoxine on cellular free fatty acid ethyl esther in ethanol treated rats Int. J. Tissue React. 15 235243.

    • Search Google Scholar
    • Export Citation
  • [25]. G. Addolorato C. Ancona E. Capristo et al.2003 Metadoxine in the treatment of acute and chronic alcoholism: a review Int. J. Immunopathol. Pharmacol. 16 207214.

    • Search Google Scholar
    • Export Citation
  • [26]. L. S. Shpilenya A. P. Mozychenko G. Gasbarrini et al.2002 Meladoxine in acute alcohol intoxication: a double blind, randomized, placebo conlrolled study Alcohol Clin. Exp. Res. 23 340346.

    • Search Google Scholar
    • Export Citation
  • [27]. Y. Z. S. Kang Y. Liu et al.2007 Pharmacokinetics of metadoxine for injection after repeated doses in healthy volunteers Chin. Med. J. 120 166168.

    • Search Google Scholar
    • Export Citation
  • [28]. F. Stickel B. Hoehn D. Schuppan H. K. Seitz 2003 Review article: Nutritional therapy in alcoholic liver disease Aliment. Pharmacol. Ther. 18 357373.

    • Search Google Scholar
    • Export Citation
  • [29]. H. Corlez-Pinto J. Chalham V. I. Chacko et al.1999 Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study JAMA 282 16591664.

    • Search Google Scholar
    • Export Citation
  • [30]. I. Guerrini C. Gentili G. Nelli M. Guazzelli 2006 A follow up study on the efficacy of metadoxine in the treatment of alcohol dependence Subst. Abuse Treat. Prev. Policy 18 35.

    • Search Google Scholar
    • Export Citation
  • [31]. M. C. Díaz Martínez A. Díaz Martínez S. V. Villamil et al.2002 Efficacy of metadoxine in the management of acute alcohol intoxication J. Int. Med. Res. 30 4451.

    • Search Google Scholar
    • Export Citation
  • [32]. L. Vonghia L. Leggio A. Ferrulli et al.2008 Acute alcohol intoxication Intern. Med. 19 561567.

  • [33]. J. Fehér G. Lengyel 2002 Pathogenesis and clinics of non-alcoholic steatohepatitis Eur. J. Gastroenterol. Hepatol. 6 185191.

  • [34]. P. Loria A. Lonardo F. Leonardi et al.2003 Non-organ-specific autoantibodies in nonalcoholic fatty liver disease Dig. Dis. Sci. 48 21732181.

    • Search Google Scholar
    • Export Citation
  • [35]. J. Fehér G. Lengyel 2003 A new approach to drug therapy in non-alcoholic steatohepatitis (NASH) J. Int. Metab. Res. 31 537551.

    • Search Google Scholar
    • Export Citation
  • [36]. A. J. McCullough 2002 Update on nonalcoholic fatty liver disease J. Clin. Gastroeneterol. 34 255262.

  • [37]. A. J. Sanyal 2002 AGA technical review on nonalcoholic fatty liver disease Gastroenterology 123 17051725.

  • [38]. G. C. Farrell C. Z. Larter 2006 Nonalcoholic fatty liver disease: from steatosis to cirrhosis Hepatology 43 Suppl.2 S99S112.

  • [39]. M. Duvnjak I. Lerotié N. Barsié et al.2007 Pathogenesis and management issues for nonalcoholic fatty liver disease World J. Gastroenterol. 13 45394550.

    • Search Google Scholar
    • Export Citation
  • [40]. O. F. James P. Day 1998 Non-alcoholic steatohepatitis (NASH): a disease or emerging identity old importance J. Hepatol. 29 495501.

    • Search Google Scholar
    • Export Citation
  • [41]. C. P. Day 2002 Non-alcoholic steatohepatitis (NASH): where are we now and where we going Gut 50 585588.

  • [42]. J. Fehér G. Lengyel Gy. Szabó 2007 Carbohydrate-deficient transferrin as a marker of alcohol consumption Hung. Med. J. 1 7382.

    • Search Google Scholar
    • Export Citation
  • [43]. H. Beck-Nielsen 2002 Insulin resistance: organ manifestation and cellular mechanisms Ugeskrift for Laeger 164 21302135.

  • [44]. J. Capeau 2003 Insulin signaling: mechanisms altered in insulin resistance Med. Sci. 19 834839.

  • [45]. M. Perez-Carreras P. Del Hoyo M. A. Martin et al.2003 Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis Hepatology 38 9991007.

    • Search Google Scholar
    • Export Citation
  • [46]. K. F. Petersen S. Dufour D. Befroy et al.2004 Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes N. Engl. J. Med. 350 664671.

    • Search Google Scholar
    • Export Citation
  • [47]. M. Sargin O. Uygur-Bayramicli H. Sargin et al.2003 Association of nonalcoholic fatty liver disease with insulin resistance: is OGTT indicated in nonalcoholic fatty liver disease? J. Clin. Gastroenterol. 37 399402.

    • Search Google Scholar
    • Export Citation
  • [48]. R. J. Seeley D. A. D'Alessio S. C. Woods 2004 Fat hormones pull their weight in the CNS Nat. Med. 10 454454.

  • [49]. M. E. Patti A. J. Butte S. Crunkhorn et al.2003 Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1 Proc. Nat. Acad. Sci. USA 100 84668471.

    • Search Google Scholar
    • Export Citation
  • [50]. E. Fraenkel I. Lazúrová J. Fehér 2004 Role of lipid peroxidation in non-alcoholic steatohepatitis Orv. Hetil. 145 611618.

  • [51]. E. Bugianesi P. Manzini S. D'Antico et al.2004 Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver Hepatology 39 179187.

    • Search Google Scholar
    • Export Citation
  • [52]. M. Haque A. J. Sanyal 2002 The metabolic abnormalities associated with non-alcoholic fatty liver disease Best Pract. Res. Clin. Gastroenterol. 59 709731.

    • Search Google Scholar
    • Export Citation
  • [53]. T. J. Hsiao J. C. Chen J. D. Wang 2004 Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients Int. J. Obes. Relat. Metab. Disord. 28 167172.

    • Search Google Scholar
    • Export Citation
  • [54]. G. Pagano G. Pacini G. Musso et al.2002 Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association Hepatology 35 367372.

    • Search Google Scholar
    • Export Citation
  • [55]. L. Valenti A. L. Fracanzani P. Dongiovanni et al.2002 Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease Gastroenterology 122 274228.

    • Search Google Scholar
    • Export Citation
  • [56]. K. Hagymási G. Lengyel E. Nagy et al.2008 Impaired antioxidant status in non-organ specific autoantibody positive patients with nonalcoholic fatty liver disease Hung. Med. J. 2 563570.

    • Search Google Scholar
    • Export Citation
  • [57]. I. Dupont D. Lucas P. Clot et al.1998 Cytochrome P4502E1 inducibility and hydroxyethyl radical formation among alcoholics J. Hepatol. 28 567571.

    • Search Google Scholar
    • Export Citation
  • [58]. D. J. Tuma 2002 Role of malondialdehyde-acetaldehyde adducts in liver injury Free Rad. Biol. Med. 32 303308.

  • [59]. D. M. Torres S. A. Harrison 2007 Current treatments in nonalcoholic steatohepatitis Curr. Treat. Opt. Gastroenterol. 10 425434.

    • Search Google Scholar
    • Export Citation
  • [60]. K. Mehta D. H. Van Thiel N. Shah et al.2004 Nonalcoholic fatty liver disease: pathogenesis and role of antioxidants Nutr. Rev. 60 289293.

    • Search Google Scholar
    • Export Citation
  • [61]. P. Lheureux A. Penaloza M. Gris 2005 Pyridoxine in clinical toxicology: a review Eur. J. Emerg. Med. 12 7885.

  • [62]. V. Calabrese A. Calderone N. Ragusa et al.1996 Effects of Metadoxine on cellular status of glutathione and of enzymatic defence system following acute ethanol intoxication in rats Drugs Exp. Clin. Res. 22 1724.

    • Search Google Scholar
    • Export Citation
  • [63]. V. Calabrese G. Randazzo N. Ragusa et al.1998 Long-term ethanol administration enhances age-dependent modulation of redox state in central and peripheral organs of rat: protection by metadoxine Drugs Exp. Clin. Res. 24 8591.

    • Search Google Scholar
    • Export Citation
  • [64]. G. Annoni L. Contu M. A. Tronci et al.1992 Pyridoxol L,2-pyrrolidon-5 carboxylate prevents active fibroplasia in CCl4-treated rats Pharmacol. Res. 25 8793.

    • Search Google Scholar
    • Export Citation
  • [65]. M. Gutierrez-Ruiz L. Bucio A. Correa et al.2001 Metadoxine prevent damage produced by ethanol and acetaldehyde in hepatocyte and hepatic stellate cells in culture Pharm. Res. 44 431436.

    • Search Google Scholar
    • Export Citation
  • [66]. S. H. Ki J. H. Choi C. W. Kim et al.2007 Combined metadoxine and garlic oil treatment efficaciously abrogates alcoholic steatosis and CYP2E1 induction in rat liver with restoration of AMPK activity Chem. Biol. Interact. 169 8090.

    • Search Google Scholar
    • Export Citation
  • [67]. P. Muriel R. Deheza 2003 Fibrosis and glycogen stores depletion induced by prolonged biliary obstruction in the rat are ameliorated by metadoxine Liver Int. 23 262268.

    • Search Google Scholar
    • Export Citation
  • [68]. Váli, L., Fehér, J., Szentmihályi, K. et al.: Metadoxine modifies both apoptotic and necrotic processes in hepatic ischaemia-reperfusion, Falk Symposium, Berlin, 2008.

    • Search Google Scholar
    • Export Citation

Clinical and Experimental Medical Journal
Language English
Size  
Year of
Foundation
2007
Publication
Programme
ceased
Volumes
per Year
 
Issues
per Year
 
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 2060-6249 (Print)
ISSN 2060-968X (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
May 2021 3 0 0
Jun 2021 3 0 0
Jul 2021 9 0 0
Aug 2021 5 0 0
Sep 2021 2 0 0
Oct 2021 6 0 0
Nov 2021 0 0 0